|
Accueil > Actualité
Bayer: hemophilia A treatment gets positive opinions
(CercleFinance.com) - Bayer's BAY94-9027 has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of hemophilia A, the German company said on Friday.
Bayer has also said that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved BAY94-9027 under the brand "Jivi" for the prophylactic treatment of hemophilia A for adults and adolescents 12 years of age or older in Japan. Copyright (c) 2018 CercleFinance.com. All rights reserved. |
19/04/2024 17:30
Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables 19/04/2024 15:53 L'Oréalentouré après ses ventes trimestrielles Tous les articles sociétés |
